Jaguar LAA acquires Johnson & Johnson Laminar assets for atrial fibrillation programme

Jaguar LAA has acquired assets from Johnson & Johnson related to the Laminar left atrial appendage closure programme, creating a newly independent medical-device company focused on advancing the technology.

The transaction transfers the Laminar programme and associated assets to Jaguar LAA, which has also brought key programme personnel into the new organisation to continue development of the left atrial appendage closure platform.

Jaguar LAA plans to advance the programme through additional development and regulatory activity, positioning the company to continue work on a potential device-based approach to reducing stroke risk in patients with atrial fibrillation.

Field	Content
Alert Type	Deal
Companies	Jaguar LAA; Johnson & Johnson
Deal Type	Asset acquisition
Asset or Company	Laminar left atrial appendage closure programme
Therapy Area(s)	Cardiology; atrial fibrillation; structural heart
Technology or Modality	Left atrial appendage closure medical device
Deal Value	Financial terms were not disclosed
Geography	United States
What Happened	Jaguar LAA acquired Johnson & Johnson assets related to the Laminar left atrial appendage closure programme and brought key programme personnel into the newly formed independent company.
Why It Matters	The transaction preserves development of the Laminar technology outside Johnson & Johnson and creates a dedicated organisation focused on advancing the programme toward further regulatory and commercial milestones.
Supporting Context	Left atrial appendage closure devices are designed to reduce stroke risk in selected patients with atrial fibrillation by isolating the appendage, where blood clots can form.
Strategic Rationale	Jaguar LAA gains control of an established medtech programme, intellectual property and experienced personnel while creating a focused development organisation around the Laminar platform.
Potential Impact	Successful development and regulatory approval could add another device-based option for stroke prevention in patients with atrial fibrillation.
Key Takeaway	Jaguar LAA has acquired the Laminar left atrial appendage closure assets from Johnson & Johnson and will continue development of the programme independently.
What to Watch	Future clinical development, regulatory submissions and financing milestones for the Laminar programme.
Primary Source	PR Newswire
Relevant Date	11 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com